Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 76

1.

Benzodiazepines and Related Drugs as a Risk Factor in Alzheimer's Disease Dementia.

Ettcheto M, Olloquequi J, Sánchez-López E, Busquets O, Cano A, Manzine PR, Beas-Zarate C, Castro-Torres RD, García ML, Bulló M, Auladell C, Folch J, Camins A.

Front Aging Neurosci. 2020 Jan 8;11:344. doi: 10.3389/fnagi.2019.00344. eCollection 2019.

2.

Neuroprotective and Neurestorative Effects of Epo and VEGF: Perspectives for New Therapeutic Approaches to Neurological Diseases.

Ureña-Guerrero ME, Castañeda-Cabral JL, Rivera-Cervantes MC, Macias-Velez RJ, Jarero-Basulto JJ, Gudiño-Cabrera G, Beas-Zárate C.

Curr Pharm Des. 2020 Jan 13. doi: 10.2174/1381612826666200114104342. [Epub ahead of print]

PMID:
31942853
3.

Role of c-Jun N-Terminal Kinases (JNKs) in Epilepsy and Metabolic Cognitive Impairment.

Busquets O, Ettcheto M, Cano A, R Manzine P, Sánchez-Lopez E, Espinosa-Jiménez T, Verdaguer E, Dario Castro-Torres R, Beas-Zarate C, X Sureda F, Olloquequi J, Auladell C, Folch J, Camins A.

Int J Mol Sci. 2019 Dec 30;21(1). pii: E255. doi: 10.3390/ijms21010255. Review.

4.

Epigallocatechin-3-Gallate (EGCG) Improves Cognitive Deficits Aggravated by an Obesogenic Diet Through Modulation of Unfolded Protein Response in APPswe/PS1dE9 Mice.

Ettcheto M, Cano A, Manzine PR, Busquets O, Verdaguer E, Castro-Torres RD, García ML, Beas-Zarate C, Olloquequi J, Auladell C, Folch J, Camins A.

Mol Neurobiol. 2019 Dec 14. doi: 10.1007/s12035-019-01849-6. [Epub ahead of print]

PMID:
31838720
5.

c-Jun N-terminal Kinase 1 ablation protects against metabolic-induced hippocampal cognitive impairments.

Busquets O, Ettcheto M, Eritja À, Espinosa-Jiménez T, Verdaguer E, Olloquequi J, Beas-Zarate C, Castro-Torres RD, Casadesús G, Auladell C, Bulló M, Folch J, Camins A.

J Mol Med (Berl). 2019 Dec;97(12):1723-1733. doi: 10.1007/s00109-019-01856-z. Epub 2019 Dec 3.

PMID:
31797011
6.

β-Caryophyllene Reduces DNA Oxidation and the Overexpression of Glial Fibrillary Acidic Protein in the Prefrontal Cortex and Hippocampus of d-Galactose-Induced Aged BALB/c Mice.

Chávez-Hurtado P, González-Castañeda RE, Beas-Zarate C, Flores-Soto ME, Viveros-Paredes JM.

J Med Food. 2019 Oct 30. doi: 10.1089/jmf.2019.0111. [Epub ahead of print]

PMID:
31663807
7.

The Involvement of Peripheral and Brain Insulin Resistance in Late Onset Alzheimer's Dementia.

Folch J, Olloquequi J, Ettcheto M, Busquets O, Sánchez-López E, Cano A, Espinosa-Jiménez T, García ML, Beas-Zarate C, Casadesús G, Bulló M, Auladell C, Camins A.

Front Aging Neurosci. 2019 Sep 6;11:236. doi: 10.3389/fnagi.2019.00236. eCollection 2019.

8.

A metabolic perspective of late onset Alzheimer's disease.

Ettcheto M, Cano A, Busquets O, Manzine PR, Sánchez-López E, Castro-Torres RD, Beas-Zarate C, Verdaguer E, García ML, Olloquequi J, Auladell C, Folch J, Camins A.

Pharmacol Res. 2019 Jul;145:104255. doi: 10.1016/j.phrs.2019.104255. Epub 2019 May 7. Review.

9.

The Recombinant Human Erythropoietin Administered in Neonatal Rats After Excitotoxic Damage Induces Molecular Changes in the Hippocampus.

Rivera-Cervantes MC, Jarero-Basulto JJ, Murguía-Castillo J, Marín-López AG, Gasca-Martínez Y, Cornelio-Martínez S, Beas-Zárate C.

Front Neurosci. 2019 Feb 19;13:118. doi: 10.3389/fnins.2019.00118. eCollection 2019.

10.

JNK Isoforms Are Involved in the Control of Adult Hippocampal Neurogenesis in Mice, Both in Physiological Conditions and in an Experimental Model of Temporal Lobe Epilepsy.

Castro-Torres RD, Landa J, Rabaza M, Busquets O, Olloquequi J, Ettcheto M, Beas-Zarate C, Folch J, Camins A, Auladell C, Verdaguer E.

Mol Neurobiol. 2019 Aug;56(8):5856-5865. doi: 10.1007/s12035-019-1476-7. Epub 2019 Jan 26.

PMID:
30685843
11.

Increased protein expression of VEGF-A, VEGF-B, VEGF-C and their receptors in the temporal neocortex of pharmacoresistant temporal lobe epilepsy patients.

Castañeda-Cabral JL, Beas-Zárate C, Rocha-Arrieta LL, Orozco-Suárez SA, Alonso-Vanegas M, Guevara-Guzmán R, Ureña-Guerrero ME.

J Neuroimmunol. 2019 Mar 15;328:68-72. doi: 10.1016/j.jneuroim.2018.12.007. Epub 2018 Dec 21.

PMID:
30597392
12.

Triple GLP-1/GIP/glucagon receptor agonists, a potential novel treatment strategy in Alzheimer's disease.

Camins A, Ettcheto M, Busquets O, Manzine PR, Castro-Torres RD, Beas-Zarate C, Verdaguer E, Sureda FX, Bulló M, Olloquequi J, Auladell C, Folch J.

Expert Opin Investig Drugs. 2019 Jan;28(1):93-97. doi: 10.1080/13543784.2019.1552677. Epub 2018 Dec 1. No abstract available.

PMID:
30480461
13.

Interactions Between Epilepsy and Plasticity.

Jarero-Basulto JJ, Gasca-Martínez Y, Rivera-Cervantes MC, Ureña-Guerrero ME, Feria-Velasco AI, Beas-Zarate C.

Pharmaceuticals (Basel). 2018 Feb 7;11(1). pii: E17. doi: 10.3390/ph11010017. Review.

14.

Peripheral and Central Effects of Memantine in a Mixed Preclinical Mice Model of Obesity and Familial Alzheimer's Disease.

Ettcheto M, Sánchez-López E, Gómez-Mínguez Y, Cabrera H, Busquets O, Beas-Zarate C, García ML, Carro E, Casadesus G, Auladell C, Vázquez Carrera M, Folch J, Camins A.

Mol Neurobiol. 2018 Sep;55(9):7327-7339. doi: 10.1007/s12035-018-0868-4. Epub 2018 Feb 5.

PMID:
29404958
15.

The Implication of the Brain Insulin Receptor in Late Onset Alzheimer's Disease Dementia.

Folch J, Ettcheto M, Busquets O, Sánchez-López E, Castro-Torres RD, Verdaguer E, Manzine PR, Poor SR, García ML, Olloquequi J, Beas-Zarate C, Auladell C, Camins A.

Pharmaceuticals (Basel). 2018 Jan 29;11(1). pii: E11. doi: 10.3390/ph11010011. Review.

16.

Memantine for the Treatment of Dementia: A Review on its Current and Future Applications.

Folch J, Busquets O, Ettcheto M, Sánchez-López E, Castro-Torres RD, Verdaguer E, Garcia ML, Olloquequi J, Casadesús G, Beas-Zarate C, Pelegri C, Vilaplana J, Auladell C, Camins A.

J Alzheimers Dis. 2018;62(3):1223-1240. doi: 10.3233/JAD-170672. Review.

17.

JNK1 inhibition by Licochalcone A leads to neuronal protection against excitotoxic insults derived of kainic acid.

Busquets O, Ettcheto M, Verdaguer E, Castro-Torres RD, Auladell C, Beas-Zarate C, Folch J, Camins A.

Neuropharmacology. 2018 Mar 15;131:440-452. doi: 10.1016/j.neuropharm.2017.10.030. Epub 2017 Oct 28.

PMID:
29111385
18.

Changes in the expression level of MAPK pathway components induced by monosodium glutamate-administration produce neuronal death in the hippocampus from neonatal rats.

Rivera-Carvantes MC, Jarero-Basulto JJ, Feria-Velasco AI, Beas-Zárate C, Navarro-Meza M, González-López MB, Gudiño-Cabrera G, García-Rodríguez JC.

Neuroscience. 2017 Dec 4;365:57-69. doi: 10.1016/j.neuroscience.2017.09.029. Epub 2017 Sep 24.

PMID:
28954212
19.

Glutamate Neonatal Excitotoxicity Modifies VEGF-A, VEGF-B, VEGFR-1 and VEGFR-2 Protein Expression Profiles During Postnatal Development of the Cerebral Cortex and Hippocampus of Male Rats.

Castañeda-Cabral JL, Beas-Zarate C, Gudiño-Cabrera G, Ureña-Guerrero ME.

J Mol Neurosci. 2017 Sep;63(1):17-27. doi: 10.1007/s12031-017-0952-7. Epub 2017 Jul 29.

PMID:
28755050
20.

Early Preclinical Changes in Hippocampal CREB-Binding Protein Expression in a Mouse Model of Familial Alzheimer's Disease.

Ettcheto M, Abad S, Petrov D, Pedrós I, Busquets O, Sánchez-López E, Casadesús G, Beas-Zarate C, Carro E, Auladell C, Olloquequi J, Pallàs M, Folch J, Camins A.

Mol Neurobiol. 2018 Jun;55(6):4885-4895. doi: 10.1007/s12035-017-0690-4. Epub 2017 Jul 27.

PMID:
28752224

Supplemental Content

Loading ...
Support Center